Novo Nordisk To Appeal Decision On Norditropin

Law360, New York (September 8, 2004, 12:00 AM EDT) -- Danish drug maker Novo Nordisk has decided to appeal a court decision that rendered its patent for recombinant human growth hormone invalid and unenforceable due to inequitable conduct.

In a decision issued on August 3, Judge Susan Robinson of the U.S. District Court for the District of Delaware dealt a blow to the world’s largest insulin maker’s bid to block Israeli generics maker Teva Pharmaceuticals Industries Ltd. and Savient Pharmaceuticals Inc. from selling human growth hormone in the U.S.

The judge said a patent owned by...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.